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ABSTRACT
Oxidized low-density lipoprotein (ox-LDL) is critical to atherosclerosis in hyperlipidemia. Bone marrow (BM)-derived endothelial progenitor cells (EPCs) are important in preventing atherosclerosis, however these cells are significantly decreased in number in hyperlipidemia. This study aimed to determine whether ox-LDL and hyperlipidemia exert similar effects on EPC populations, and to investigate the involvement of reactive oxygen species (ROS). ROS production in BM and blood was significantly increased in male C57BL/6 mice treated with intravenous ox-LDL, and in hyperlipidemic LDL receptor knockout mice fed with a 4-month high-fat diet. ROS formation was effectively blocked by overexpression of antioxidant enzymes or N-acetylcysteine treatment. In both hyperlipidemic and ox-LDL-treated mice, the number of c-Kit by inhibiting ROS production. These data suggested that ox-LDL produced significant changes in BM and blood EPC populations, largely similar to chronic hyperlipidemia, via predominantly ROS-independent mechanism(s).
INTRODUCTION
Endothelial dysfunction or injury is considered one of the major factors that contribute to the development of atherosclerosis and coronary heart disease (1,2). Endothelial progenitor cells (EPCs) play a critical role in vascular re-endothelialization, angiogenesis, and prevention of neointima formation after vascular injury (3) (4) (5) (6) . It is well known that the number and function key component in the hyperlipidemic state, has been implicated in the formation of atherosclerotic plaques. The serum ox-LDL level is significantly increased in the patients with stable CAD and further increased in patients with acute coronary syndrome (9-11). There are extensive interactions between ox-LDL and a variety of cells through multiple mechanisms. The outcomes of the interactions between ox-LDL and its target cells are highly variable and complex, depending on the individual cell types. Ox-LDL promotes proliferation of macrophages and vascular smooth muscle cells, and inhibits apoptosis of macrophages and monocytes through activation of the PI-3 kinase/PKB and mitogenactivated protein kinase (MAPK) pathways (12) (13) (14) (15) (16) . In contrast, ox-LDL inhibits proliferation and promotes apoptosis of vascular endothelial cells (7, 17) . Ox-LDL also inhibits EPC proliferation and differentiation, and suppresses EPC function, including inhibition of migration, adhesion, in vitro vasculogenesis, and ischemia-induced neovascularization in vivo (17) (18) (19) (20) (21) . However, it is not known whether ox-LDL has similar effects on EPCs in vivo as hyperlipidemia.
Oxidative stress with reactive oxidative species (ROS) formation plays a critical role in the development of atherosclerosis (3, (22) (23) (24) (25) (26) . ROS generation in monocytes is increased in hyperlipidemic patients with an elevated plasma ox-LDL level. Exposure to ox-LDL increases intracellular ROS formation in cultured endothelial cells (27, 28) . In vitro studies demonstrated that a significant amount of ROS was produced spontaneously from ox-LDL at clinically relevant concentrations, and played an important role in the action of ox-LDL on bone marrow stem cells, including expression of the stem cell specific marker Oct-4, cell proliferation, and endothelial differentiation (29, 30) .
The present study was to determine whether ox-LDL produced changes similar to hyperlipidemia in EPC populations in vivo, at least partially through ROS formation. One of the challenges in this type of study is to correctly identify EPCs (31) (32) (33) 
MATERIALS AND METHODS

Ox-LDL preparation
Following Institutional Review Board approval, blood was collected in heparinized tubes from consented adult healthy donors, and stored on ice. Plasma was obtained from the blood after centrifuging at 1500g for 20 min. Lipoproteins were isolated from the plasma using sequential ultracentrifugation with a Beckman TL-100 tabletop ultracentrifuge (Beckman, Palo Alto, CA) as described (34) . The isolated lipoproteins were dialyzed against 0.3 mM EDTA in 1x phosphate buffered saline (PBS, pH 7.4) overnight and subsequently sterilized with 0.22 μM filter. The protein concentration in the lipoproteins was determined using the Lowry method. Ox-LDL was produced from the native LDL immediately after dialysis using 5 μM copper sulfate and was stopped by adding EDTA (0.25 mM, final concentration) as described (35) .
Animal models and ox-LDL treatment
All animal experiments were performed in accordance with the "Guide for the Care and Use of Laboratory Animals of the US National Institutes of Health". The experimental protocols for the present study were reviewed and approved by the Institutional Animal Care and Use Committee of the Ohio State University Wexner Medical Center, Columbus, OH, USA. Wild-type male C57 BL/6 mice (4-6 weeks old, Jackson Lab, ME, USA) were given 50 µg ox-LDL via tail vein injection (once daily for 3 days). To evaluate the role of ROS formation in the action of ox-LDL, the mice were pre-treated with NAC (in the drinking water) for 24 hours prior to ox-LDL administration.
To further evaluate the role of ROS production in mediating the effects of ox-LDL, a triple-transgenic (TG) mouse model (on C57 BL/6 background; 4-6 weeks old, male) with concomitant global overexpression of an antioxidant network (AON) composed of SOD1, SOD3, © 1996-2015 and glutathione peroxidase (GSHPx)-1 was used to repeat the experiment, with littermate WT male mice as the control (36) . TG mice were confirmed by genotyping and increased protein expression of the enzymes (using Western blot analysis) as well as increased enzyme activities as shown in Figure 5 . To determine whether NAC treatment or AON expression affected the distribution and clearance of ox-LDL in vivo, the ox-LDL levels in the serum and bone marrow (BM) were measured at different time points after a single ox-LDL (50 µg) injection using a human ox-LDL ELISA kit (Mercodia Inc. Winston Salem, NC). To determine if ox-LDL could produce the effects on EPCs similar to hyperlipidemia, homozygous LDL receptor knockout (LDLR -/-) mice (6-8 weeks old, on C57 BL/6 background, Jackson Lab, ME, US) were fed with a high fat diet (HFD) (17% AMF; 0.2% cholesterol) for 4 months to induce hyperlipidemia, with or without NAC treatment (in the drinking water) (37) . Age-matched LDLR -/-C57BL/6 mice with normal diet were used as control. The mouse serum lipid profile was quantitatively determined using a lipid profile analyzer and cassette (Cholestech LDX, CA, US) to confirm the establishment of hyperlipidemic state.
Intracellular and extracellular ROS detection
Blood was collected from the mice, and red blood cells (RBCs) were eliminated using RBC lysis as described (38) . The level of intracellular ROS formation in blood cells after injection of ox-LDL was determined using the ROS Detection Reagents-FITC DCF (Invitrogen) as described (39) . The cells were incubated with the reagent at the concentration of 5 µg/ml for 10 min at 37°C. The labeled cells were washed twice with PBS and then suspended in warm PBS for analysis using flow cytometry. The fluorescence-positive cells were quantitatively evaluated using an LSRII (BD Bioscience, CA, USA) at the wavelength of 525nm as described (40) . Extracellular ROS formation in the serum was quantitatively determined using the ex vivo electron paramagnetic resonance (EPR) spectroscopy with 5-diethoxyphosphoryl-5-methyl-1-pyrroline N-oxide (DEPMPO) (Santa Cruz) as the spin trap as described. ROS production was measured using EPR spectroscopy through a mixture of 50 mM DEPMPO (final concentration) with serum as described (29).
Murine EPC analysis
To determine the effect of ox-LDL or hyperlipidemic state on the populations of BM and blood EPCs, BM and blood cells were harvested in the mice after injection of 50 µg ox-LDL for 3 days, and in the hyperlipidemic LDLR -/-mice after 4 months of HFD with and without NAC treatment. After elimination of RBC with RBC lysis buffer, multicolor analysis for BM and blood EPCs was performed using an LSRII system (Becton Dickinson Biosciences, NJ, USA). A variety of cell surface markers and their combinations for identification of BM and blood EPCs were used as described (41- 
Statistical analysis
All the data were presented as means ± standard deviation (SD), and statistically analyzed using unpaired Student t-test (two-sided) for two groups of data or one way ANOVA (analysis of variance) (PRISM Version 4.0.; GraphPad Software, Inc., San Diego, CA) followed by post hoc conservative Tukey's test for three or more groups of data to minimize type I error as appropriate. The differences were considered statistically significant when a two-tailed p < 0.05.
RESULTS
Measurable level of ox-LDL in BM and blood
To evaluate the effect of ox-LDL on EPC populations, we first determined if ox-LDL was present in the BM and blood after IV administration. As shown in Figure 1A , after a single intravenous injection of human ox-LDL in WT C57BL/6 mice, a significant level of ox-LDL was detected in the blood within 2 min of injection, and declined rapidly thereafter. No detectable level of ox-LDL was present in the blood after 10 min. In the BM, the ox-LDL level increased within 2 min, peaked at 5 min, remained stable for 10 min, then declined rapidly thereafter ( Figure 1B ).
Ox-LDL significantly altered EPC populations in BM and blood
BM and blood cells were collected for EPC analysis after ox-LDL treatment. Flow cytometry analysis showed that ox-LDL significantly decreased the population of c-Kit + /CD31 + cells in BM ( Figure 2A and Tables 2 and 4 
Ox-LDL produced mostly similar changes in EPC populations as hyperlipidemia
Next, we compared the changes in EPC populations in the BM and blood in ox-LDL-treated and © 1996-2015 hyperlipidemic mice. Hyperlipidemia was confirmed by serum analysis (Table 1) . In both groups, the number of c-Kit , and Tables 3-4) . However, there were also some differences between Figure 2F and Tables 3-4).
Ox-LDL and hyperlipidemia increased extracellular ROS production in BM and blood, but only increased intracellular ROS production in blood
Ox-LDL treatment induces significant ROS generation in vitro (29) . We observed that both extracellular and intracellular ROS levels were significantly increased in the blood within 10 min of IV injection of ox-LDL ( Figure  3B and 4B). The extracellular ROS level in the BM of ox-LDL-treated animals were also significantly increased ( Figure 3A) , while there was no difference in intracellular ROS formation in the BM ( Figure 4A ). Hyperlipidemia induced similar changes to ox-LDL treatment ( Figure 3A and 3B, Figure 4B ).
NAC treatment or overexpression of antioxidant enzymes blocked ox-LDL-induced ROS production
To determine the role of ROS production in mediating the effects of ox-LDL and hyperlipidemia on EPC populations in BM and blood, mice were treated with NAC to inhibit ROS formation. We also used a triple-transgenic (TG) mouse model that over-expressed a network of antioxidant enzymes (SOD-1, SOD-3 and Gpx-1); the protein levels and activities of these enzymes were significantly increased in the transgenic mice ( Figure 5 ). As expected, the blood intracellular and extracellular ROS and BM extracellular ROS production induced by ox-LDL were effectively blocked in the NACtreated mice and in the transgenic mice ( Figure 3 and Figure 4B ). The distribution and clearance of ox-LDL were not affected in either group ( Figure 1C and 1D) . Similarly, extracellular and intracellular ROS formation 
Inhibition of ROS production only partially reversed the effects of ox-LDL and hyperlipidemia on EPC populations
Next, we examined if inhibition of ROS production could prevent the effects of ox-LDL and hyperlipidemia on EPC populations. Some changes in blood EPC populations induced by ox-LDL or hyperlipidemia were reversed by NAC treatment. As shown in Figure 2C and Tables 3-4 Table 2 -4) . These data suggested that ox-LDL and hyperlipidemia-induced changes in EPCs in BM and blood were mediated by both ROS-dependent and ROSindependent mechanisms depending on the individual cell populations. 
DISCUSSION
In the present study, we demonstrated that ox-LDL treatment induced generation of ROS in the BM and blood, and significantly altered the populations of EPCs in the BM and blood in a similar manner to chronic hyperlipidemia. Our data suggested that these changes involved both ROS-dependent and predominantly ROS-independent mechanisms in vivo. This was the first demonstration that ox-LDL was at least partially responsible for the altered number of EPCs in hyperlipidemic states, and support the concept that ox-LDL is a critical component of hyperlipidemia.
The outcomes of the interactions between ox-LDL and its target cells are variable and complex depending on the individual cell type. Ox-LDL promotes proliferation of macrophages and vascular smooth muscle cells, and inhibits apoptosis of macrophages and monocytes (12-16, 48, 49) . Low level of ox-LDL has been reported to stimulate the proliferation, migration, and adhesion of mouse BM mesenchymal stem cells (50) . On the other hand, ox-LDL inhibits proliferation and promotes apoptosis of vascular endothelial cells and EPCs (7, 17, 51) . Recently, we have demonstrated that ox-LDL inhibits cell proliferation, induces apoptosis of rat BM multipotent adult progenitor cells (MAPCs), and attenuates their endothelial differentiation (30) . Similarly, in the present study, ox-LDL produced a complex change in the cell populations in both BM and blood: some cell populations were selectively increased, while others decreased. The total number of murine BM cell and EPC percentile were determined in the mice with different treatments as mean±SD. ). An important mechanism for the actions of ox-LDL is ROS formation and oxidative stress. Ox-LDL is a rich source of ROS that are directly related to tissue oxidative stress, and the development and progression of cardiovascular diseases like hypertension and atherosclerosis (53) (54) (55) (56) . Recently, we demonstrated that ox-LDL induced the generation of ROS spontaneously in vitro that was completely prevented when the antioxidant NAC was present (29) . In the present study, we showed that intravenous injection of ox-LDL also produced a significant level of ROS in BM and blood in vivo similar to hyperlipidemia. ROS and oxidative stress are involved in EPC dysfunction in many diseases, including hyperlipidemia, diabetes, coronary artery disease and renal ischemia-reperfusion injury (57) (58) (59) . We observed here that in both hyperlipidemic and ox-LDL-treated mice, the c-Kit + /CD31 + cell population was significantly decreased in both BM and blood, and the number of Sca-1 + /Flk-1 + cells was significantly decreased in blood without change in BM. Blocking ROS formation using a transgenic antioxidant mouse model or treatment with NAC had no significant impact on the changes in the populations of these cells. These (60) . This might reflect a differential response to hyperlipidemia in mice and humans for this particular cell population.
The mechanisms for the alterations of BM and blood EPCs in hyperlipidemia are complex and remain largely unknown. Although several similarities in the changes of EPC populations in ox-LDL-treated mice and mice with hyperlipidemia were observed in the present study, there were also differences, notably in the blood CD34 + /CD133 + population. NAC treatment or AON overexpression had no effect on changes in this population induced by ox-LDL or hyperlipidemia, suggesting a role for factors other than ox-LDL. This finding is perhaps not surprising, since the oxidative modification of LDL is very complex in hyperlipidemic animals, with generation of many modified lipoprotein ligands in addition to ox-LDL (61,62).
ROS-independent mechanisms played a critical role in the overall changes in EPC populations in BM and blood in response to ox-LDL exposure and in the setting of hyperlipidemia. This may provide an explanation for the controversy and dilemma in view of the critical role of BM-derived EPCs in maintaining the integrity of endothelial structure and function. It is believed that oxidative stress and excessive ROS production are important to the development of cardiovascular diseases in hyperlipidemia. However, despite strong pre-clinical evidence and promising data in animal studies, most clinical trials on antioxidants including vitamin E or β-carotene have failed to demonstrate a significant clinical benefit in patients with hyperlipidemia and cardiovascular diseases (63) . The data from the present study showed that blocking ROS production from ox-LDL or hyperlipidemia either had no effect on restoring the decreased EPC number or preventing the increase of EPC subpopulation like circulating CD34 + /
Flk-1 + cell. Clearly, the mechanisms for the alteration of EPC populations in response to ox-LDL exposure and hyperlipidemia are complex and require further investigation (22, 64) .
In conclusion, we have shown that ox-LDL and hyperlipidemia produced similar but not identical changes in the EPC populations in BM and blood, predominantly through mechanism(s) independent of ROS formation. Further studies are needed to investigate these mechanisms and to characterize the functional status of the individual EPC subgroups that change in response to ox-LDL and hyperlipidemia.
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